Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indices continue to trade weak
Wed, 3 Apr 01:30 pm

Backed by persistent selling, Indian stock markets continued to trade in the red in the previous two trading hours. Barring stocks from the power and healthcare sectors, all other sectors are trading in the negative territory. Stocks from consumer durables and auto sector are witnessing highest selling pressure.

BSE-Sensex is down by 68 points and NSE-Nifty is trading down by 23 points. While BSE Mid Cap is trading up by 0.35%, BSE Small Cap index is trading up by 0.77%. The rupee is trading at 54.36 to the US dollar.

Most of the domestic pharma stocks are trading in the green with Elder Pharma and Natco Pharma being among the gainers. As per a leading daily, MNC pharma company Merck Sharp & Dohme (MSD) has filed a suit in the Delhi High Court against Glenmark for violating patents on MSD's diabetes drugs Januvia and Janumet. Glenmark has launched both the drugs in the Indian market, before the patent expiry of the said drugs. Patents allow innovator companies a 20-year exclusivity on manufacture and distribution and MSD had launched its products in 2008 in the Indian market. Reportedly, Glenmark has launched the drug in the Indian market at 30% discount than Merck's price. Both Merck's drugs are priced at about Rs 42 for a day's dose. While Januvia or sitagliptin phosphate is a once-a-day prescription, Janumet or Sitagliptin Metformin is taken twice a day. Sun Pharma is also selling the said drugs in the Indian market. However, the company has launched these drugs as per a deal with MSD. Glenmark's launch will not only impact MSD's market but might also eat into Sun Pharma's market share. The stock of Glenmark is trading down by 2%, while that of Sun is trading up by 2%.

Majority of the FMCG stocks are trading in the green with Dabur and Colgate among the major gainers. As per a leading financial daily, FMCG behemoth Hindustan Unilever (HUL) has launched its premium ice cream brand 'Magnum' in Chennai. The ice cream is priced at Rs 75 for a stick and has been launched in three flavours - Classic, Almond and Chocolate Truffle. As per the company, the brand is targeted at the youth population. HUL has chosen Chennai to be the first market for its launch due to its affluent consumer base that is open to new and different experiences. Magnum ice cream is currently available in Europe and across the US as well as Asian countries such as Thailand, Indonesia, Malaysia and Philippines. The company currently sells 1 bn units of Magnum annually. HUL stock is currently down 1.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indices continue to trade weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.